Health Canada released a revised Guidance Document: Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs on June 28, 2019, effective immediately. Revisions include clarifying additions on the requirements for cross-licensed products for an Administrative Certification Form and Letter of Authorization, a Drug Notification form and labelling.
Health Canada has also released an updated Good Label and Package Practices Guide for Prescription Drugs. The June 21, 2019 update introduces only administrative edits to the 2016 guidance on labelling and packaging of prescription pharmaceuticals, biologics, and radiopharmaceuticals under Health Canada’s Plain Language Labelling Initiative.
Related Publications & Articles
-
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More